Ecole Normale Superieure de Lyon
Lyon, France
Time filter
Source Type

Ecole Normale Superieure de Lyon and French National Center for Scientific Research | Date: 2015-05-15

The invention relates to a pharmaceutical or probiotic composition comprising at least one Lactobacillus strain with intestinal tropism, especially selected from the species Lactobacillus plantarum, Lactobacillus fermentum and Lactobacillus casei, used to stimulated juvenile growth in cases of malnutrition especially characterised by a protein deficiency. The strains can be selected from a vinegar fly model and/or a mouse model. The invention also relates to a method for probiotic treatment using said composition.

Kallistem, French National Center for Scientific Research, French National Institute for Agricultural Research and Ecole Normale Superieure de Lyon | Date: 2014-12-19

The present invention relates to a process for in vitro spermatogenesis from male germinal tissue comprising conducting maturation of testicular tissue comprising germ cells in a bioreactor which is made of a biomaterial and comprises at least one cavity wherein the germinal tissue is placed, and recovering elongated spermatids and/or spermatozoa.

Ecole Normale Superieure de Lyon, University of Lyon and French National Center for Scientific Research | Date: 2014-04-29

The invention concerns a new class of tubulin polymerisation inhibitors and their applications in research and medicine, notably in chemotherapy. The invention proposes new azoaryl derivatives of formula (I): as defined in Claim 1, which may be fully reversibly interconverted between non-tubulin-binding trans and tubulin-binding as isomeric forms, either by irradiation or spontaneously. The invention also concerns compounds with a azoaryl structure for use in studying the cytoskeleton and/or its associated processes, or in the treatment of a disease for which a tubulin polymerisation inhibition activity has a beneficial effect, wherein the compound is administered to the cell, organism or patient in need of such treatment in the trans form of the diazenyl bond, and where this trans form is inactive as regards a tubulin polymerisation inhibition effect, and where after photoisomerisation in vitro, in cellulo or in vivo to an azoaryl compound in its cis isomeric form of the diazenyl bond by the application of light, optionally with modification in vitro, in cellulo or in vivo of one or more substituents, the resultant cis form is active as regards a tubulin polymerisation inhibition effect.

Ecole Normale Superieure de Lyon, University of Lyon and French National Center for Scientific Research | Date: 2015-06-24

The invention provides probes with formula (I): in which:

Agency: European Commission | Branch: H2020 | Program: RIA | Phase: EINFRA-5-2015 | Award Amount: 4.84M | Year: 2015

E-CAM will create, develop and sustain a European infrastructure for computational science applied to simulation and modelling of materials and of biological processes of industrial and societal importance. Building on the already significant network of 15 CECAM centres across Europe and the PRACE initiative, it will create a distributed, sustainable centre for simulation and modelling at and across the atomic, molecular and continuum scales. The ambitious goals of E-CAM will be achieved through three complementary instruments: 1. development, testing, maintenance, and dissemination of robust software modules targeted at end-user needs; 2. advanced training of current and future academic and industrial researchers able to exploit these capabilities; 3. multidisciplinary, coordinated, top-level applied consultancy to industrial end-users (both large multinationals and SMEs). The creation and development of this infrastructure will also impact academic research by creating a training opportunity for over 300 researchers in computational science as applied to their domain expertise. It will also provide a structure for the optimisation and long-term maintenance of important codes and provide a route for their exploitation. Based on the requests from its industrial end-users, E-CAM will deliver new software in a broad field by creating over 200 new, robust software modules. The modules will be written to run with maximum efficiency on hardware with different architectures, available at four PRACE centres and at the Hartree Centre for HPC in Industry. The modules will form the core of a software library (the E-CAM library) that will continue to grow and provide benefit well beyond the funding period of the project. E-CAM has a 60 month duration, involves 48 staff years of effort, has a total budget of 5,836,897 and is requesting funding from the EC of 4,836,897, commensurate with achieving its ambitious goals.

Agency: European Commission | Branch: H2020 | Program: RIA | Phase: Health | Award Amount: 2.85M | Year: 2014

The ongoing Ebola outbreak in West Africa is the largest and deadliest the world has ever seen. In September 2014, the number of EBOV cases exceeded the total of all cases from previous known outbreaks. Further, this public health crisis shifted into a complex emergency, with significant, social, economic, humanitarian, political and security dimensions. Till date, no effective medicine has been proven to be effective against EBOV. As a result, it is immensely difficult to mitigate the current outbreak as well as prevent further outbreaks in this region. On Sept 4-5 2014, the WHO gathered expertise on experimental therapies and vaccines and their role in containing the Ebola outbreak in West Africa. During this consultation, experts identified several therapeutic and vaccine interventions that should be the focus of priority evaluation. Among these candidates is the existing antiviral drug Favipiravir, that has proven activity against many RNA viruses in vivo and in vitro including Ebola. Favipiravir is known to inhibit viral gene replication within infected cells to prevent propagation among which it inhibits viral gene replication within infected cells to prevent propagation. Hence, Favipiravir is currently aimed as a curative option in severe pandemic flue. Furthermore, there is currently enough stock of Favipiravir to even treat more than 20.000 patients, and the producer of Favipiravir, Toyoma Chemical/Fujifilm in Japan is willing to rapidly upscale the production of this drug. This drug has been extensively tested in humans and approved in Japan for treatment and prevention of influenza. The drug has shown an excellent safety profile in more than 2000 patients tested and no major adverse effect were reported. The current crisis requires both an immediate response to treat patients and prevent the further spread of the epidemic, as well as long term commitment in the complex sociocultural context. REACTION! will address both needs.

Agency: European Commission | Branch: H2020 | Program: IA | Phase: DRS-03-2015 | Award Amount: 21.10M | Year: 2016

Effective EU support to a large external crisis requires new approaches. In response to this challenge and to identified user and market needs from previous projects, Reaching Out proposes an innovative multi-disciplinary approach that will optimize the efforts, address a wide spectrum of users and maximize market innovation success. This approach results in five main objectives: to 1. Develop a Collaborative Framework, with distributed platforms of functional services, 2. Implement a flexible and open collaborative innovation process involving users and SMEs, suppliers, operators and research organisations, 3. Develop, upgrade and integrate 78 new connectable and interoperable tools, 4. Conduct 5 large scale demonstrations on the field: o health disaster in Africa (Epidemics in Guinea, with strong social and cultural issues), o natural disaster in a politically complex region and a desert environment (Earthquake in the Jordan Valley, led jointly by Jordan, Israel and Palestine), o three global change disasters in Asia targeted at large evacuation and humanitarian support in Bangladesh (long lasting floods, huge storms and associated epidemics,), EU citizen support and repatriation in Shanghai (floods & storm surge), radiological and industrial disasters impacting EU assets in Taiwan (flash floods, landslides, storm surge and chemical and radiological disasters), supported and co-funded by local authorities, 5. Provide recommendations and evaluations for future legal and policy innovations. The project will be conducted under the supervision of senior end-users. It will be performed with flexible and proven procedures by a balanced consortium of users, industry, innovative SMEs, RTO and academia in the EU and the demonstration regions. The main expected impact is to improve external disaster and crisis management efficiency and cost-benefit and increase the EU visibility whilst enhancing EU industry competitiveness and enlarging the market.

Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-22-2016 | Award Amount: 6.34M | Year: 2017

Next-Lab intends to change the educational landscape of science and technology education in Europe on a very large scale. The project offers a unique and extensive collection of interactive online (virtual and remote) laboratories that, through a process of mixing and re-use, can be straightforwardly and efficiently combined with dedicated support tools (learning apps) and multimedia material to truly form open, cloud-based, shareable educational resources with an embedded pedagogical structure. Next-Lab offers extensive opportunities for localisation and personalisation together with analytics facilities monitoring students progress and achievements. Next-Lab is designed to rely on full co-creation with users in combination with rapid development and testing cycles. Next-Lab builds on the highly successful (FP7) Go-Lab project that already offers online labs, inquiry learning apps, and authoring facilities for inquiry learning. To amplify the existing impact to the next-level innovation stage, Next-Lab extends the Go-Lab system with tools for the learning of 21st century skills, facilities for self- and peer-assessment and portfolio development, as well as opportunities to include learning by modeling. Next-Lab will cover secondary and also primary education, to ensure an early positive attitude towards science and technology and the continuous availability of innovative learning material throughout students school career. To guarantee long-term impact, Next-Lab also addresses the teachers of the future by its presence in pre-service teacher training programs throughout Europe. To evaluate its impact, Next-Lab combines usage data analysis techniques for very large-scale pilots with in-depth, qualitative, case-based, assessments. Next-Lab prepares for a following sustainable stage of the product. As it builds upon and extends existing networks of teachers, professional associations, and policymakers, the impact of Next-Lab will be massive.

Yvert G.,Ecole Normale Superieure de Lyon
Trends in Genetics | Year: 2014

Genotype-phenotype relations are usually inferred from a deterministic point of view. For example, quantitative trait loci (QTL), which describe regions of the genome associated with a particular phenotype, are based on a mean trait difference between genotype categories. However, living systems comprise huge numbers of cells (the 'particles' of biology). Each cell can exhibit substantial phenotypic individuality, which can have dramatic consequences at the organismal level. Now, with technology capable of interrogating individual cells, it is time to consider how genotypes shape the probability laws of single cell traits. The possibility of mapping single cell probabilistic trait loci (PTL), which link genomic regions to probabilities of cellular traits, is a promising step in this direction. This approach requires thinking about phenotypes in probabilistic terms, a concept that statistical physicists have been applying to particles for a century. Here, I describe PTL and discuss their potential to enlarge our understanding of genotype-phenotype relations. © 2013 The Author.

French Institute of Health, Medical Research and Ecole Normale Superieure de Lyon | Date: 2016-03-10

The invention relates to the generation and the use of hepacivirus pseudo-particles containing native functional E1, E2 envelope glycoproteins assembled onto retroviral core particles. These particles are highly infectious and constitute a valid model of hepacivirus virion.

Loading Ecole Normale Superieure de Lyon collaborators
Loading Ecole Normale Superieure de Lyon collaborators